U.S. Code > Title 21 > Chapter 22 > § 1704 - Coordination with National Drug Control Program agencies in demand reduction, supply reduction, and State and local affairs
Current as of: February 2010 (a) Timing, contents, and process for development and submission of
National Drug Control Strategy
(1) Timing
Not later than February 1 of each year, the President shall
submit to Congress a National Drug Control Strategy, which shall
set forth a comprehensive plan for the year to reduce illicit
drug use and the consequences of such illicit drug use in the
United States by limiting the availability of, and reducing the
demand for, illegal drugs.
(2) Contents
(A) In general
The National Drug Control Strategy submitted under paragraph
(1) shall include the following:
(i) Comprehensive, research-based, long-range, quantifiable
goals for reducing illicit drug use and the consequences of
illicit drug use in the United States.
(ii) Annual quantifiable and measurable objectives and
specific targets to accomplish long-term quantifiable goals
that the Director determines may be achieved during each year
beginning on the date on which the National Drug Control
Strategy is submitted.
(iii) A 5-year projection for program and budget
priorities.
(iv) A review of international, State, local, and private
sector drug control activities to ensure that the United
States pursues coordinated and effective drug control at all
levels of government.
(v) An assessment of current illicit drug use (including
inhalants and steroids) and availability, impact of illicit
drug use, and treatment availability, which assessment shall
include -
(I) estimates of drug prevalence and frequency of use as
measured by national, State, and local surveys of illicit
drug use and by other special studies of nondependent and
dependent illicit drug use;
(II) illicit drug use in the workplace and the
productivity lost by such use; and
(III) illicit drug use by arrestees, probationers, and
parolees.
(vi) An assessment of the reduction of illicit drug
availability, as measured by -
(I) the quantities of cocaine, heroin, marijuana,
methamphetamine, ecstasy, and other drugs available for
consumption in the United States;
(II) the amount of marijuana, cocaine, heroin,
methamphetamine, ecstasy, and precursor chemicals and other
drugs entering the United States;
(III) the number of illicit drug manufacturing
laboratories seized and destroyed and the number of
hectares of marijuana, poppy, and coca cultivated and
destroyed domestically and in other countries;
(IV) the number of metric tons of marijuana, heroin,
cocaine, and methamphetamine seized and other drugs; and
(V) changes in the price and purity of heroin,
methamphetamine, and cocaine, changes in the price of
ecstasy, and changes in tetrahydrocannabinol level of
marijuana and other drugs.
(vii) An assessment of the reduction of the consequences of
illicit drug use and availability, which shall include -
(I) the burden illicit drug users placed on hospital
emergency departments in the United States, such as the
quantity of illicit drug-related services provided;
(II) the annual national health care cost of illicit drug
use; and
(III) the extent of illicit drug-related crime and
criminal activity.
(viii) A determination of the status of drug treatment in
the United States, by assessing -
(I) public and private treatment utilization; and
(II) the number of illicit drug users the Director
estimates meet diagnostic criteria for treatment.
(ix) A review of the research agenda of the Counterdrug
Technology Assessment Center to reduce the availability and
abuse of drugs.
(x) A summary of the efforts made to coordinate with
private sector entities to conduct private research and
development of medications to treat addiction by -
(I) screening chemicals for potential therapeutic value;
(II) developing promising compounds;
(III) conducting clinical trials;
(IV) seeking Food and Drug Administration approval for
drugs to treat addiction;
(V) marketing the drug for the treatment of addiction;
(VI) urging physicians to use the drug in the treatment
of addiction; and
(VII) encouraging insurance companies to reimburse the
cost of the drug for the treatment of addiction.
(xi) An assessment of Federal effectiveness in achieving
the National Drug Control Strategy for the previous year,
including a specific evaluation of whether the objectives and
targets for reducing illicit drug use for the previous year
were met and reasons for the success or failure of the
previous year's Strategy.
(xii) A general review of the status of, and trends in,
demand reduction activities by private sector entities and
community-based organizations, including faith-based
organizations, to determine their effectiveness and the
extent of cooperation, coordination, and mutual support
between such entities and organizations and Federal, State,
local, and tribal government agencies.
(xiii) Such additional statistical data and information as
the Director considers appropriate to demonstrate and assess
trends relating to illicit drug use, the effects and
consequences of illicit drug use (including the effects on
children of substance abusers), supply reduction, demand
reduction, drug-related law enforcement, and the
implementation of the National Drug Control Strategy.
(xiv) A supplement reviewing the activities of each
individual National Drug Control Program agency during the
previous year with respect to the National Drug Control
Strategy and the Director's assessment of the progress of
each National Drug Control Program agency in meeting its
responsibilities under the National Drug Control Strategy.
(B) Classified information
Any contents of the National Drug Control Strategy that
involve information properly classified under criteria
established by an Executive order shall be presented to
Congress separately from the rest of the National Drug Control
Strategy.
(C) Selection of data and information
In selecting data and information for inclusion under
subparagraph (A), the Director shall ensure -
(i) the inclusion of data and information that will permit
analysis of current trends against previously compiled data
and information where the Director believes such analysis
enhances long-term assessment of the National Drug Control
Strategy; and
(ii) the inclusion of data and information to permit a
standardized and uniform assessment of the effectiveness of
drug treatment programs in the United States.
(3) Process for development and submission
In developing and effectively implementing the National Drug
Control Strategy, the Director -
(A) shall consult with -
(i) the heads of the National Drug Control Program
agencies;
(ii) Congress;
(iii) State, local, and tribal officials;
(iv) private citizens and organizations, including
community and faith-based organizations with experience and
expertise in demand reduction;
(v) private citizens and organizations with experience and
expertise in supply reduction; and
(vi) appropriate representatives of foreign governments;
(B) in satisfying the requirements of subparagraph (A), shall
ensure, to the maximum extent possible, that State, local, and
tribal officials and relevant private organizations commit to
support and take steps to achieve the goals and objectives of
the National Drug Control Strategy;
(C) with the concurrence of the Attorney General, may require
the El Paso Intelligence Center to undertake specific tasks or
projects to support or implement the National Drug Control
Strategy; and
(D) with the concurrence of the Director of National
Intelligence and the Attorney General, may request that the
National Drug Intelligence Center undertake specific tasks or
projects to support or implement the National Drug Control
Strategy.
(b) Submission of revised strategy
The President may submit to Congress a revised National Drug
Control Strategy that meets the requirements of this section -
(1) at any time, upon a determination of the President, in
consultation with the Director, that the National Drug Control
Strategy in effect is not sufficiently effective; or
(2) if a new President or Director takes office.
(c) Performance measurement system
Not later than February 1 of each year, the Director shall submit
to Congress as part of the National Drug Control Strategy, a
description of a national drug control performance measurement
system, that -
(1) develops 2-year and 5-year performance measures and targets
for each National Drug Control Strategy goal and objective
established for reducing drug use, availability, and the
consequences of drug use;
(2) describes the sources of information and data that will be
used for each performance measure incorporated into the
performance measurement system;
(3) identifies major programs and activities of the National
Drug Control Program agencies that support the goals and annual
objectives of the National Drug Control Strategy;
(4) evaluates the contribution of demand reduction and supply
reduction activities as defined in section 1701 of this title
implemented by each National Drug Control Program agency in
support of the National Drug Control Strategy;
(5) monitors consistency between the drug-related goals and
objectives of the National Drug Control Program agencies and
ensures that each agency's goals and budgets support and are
fully consistent with the National Drug Control Strategy; and
(6) coordinates the development and implementation of national
drug control data collection and reporting systems to support
policy formulation and performance measurement, including an
assessment of -
(A) the quality of current drug use measurement instruments
and techniques to measure supply reduction and demand reduction
activities;
(B) the adequacy of the coverage of existing national drug
use measurement instruments and techniques to measure the
illicit drug user population, and groups that are at risk for
illicit drug use;
(C) the adequacy of the coverage of existing national
treatment outcome monitoring systems to measure the
effectiveness of drug abuse treatment in reducing illicit drug
use and criminal behavior during and after the completion of
substance abuse treatment; and
(D) the actions the Director shall take to correct any
deficiencies and limitations identified pursuant to
subparagraphs (A) and (B) of this subsection.
(d) Modifications
A description of any modifications made during the preceding year
to the national drug performance measurement system described in
subsection (c) shall be included in each report submitted under
subsection (b).Legislative History ________________________________________________________________________
Questions & Answers: Drugs and AlcoholU.S. Code Provisions: Drugs and AlcoholState Laws: Drugs and Alcohol
 |
Email
Print
